New biomedical project starts construction in WND

Construction started on the research and development and production headquarters and the global biomedical innovation incubation center of Dizal Pharmaceutical in the Wuxi National Hi-tech District on Jan 11.

The company will invest about 1 billion yuan ($157.16 million) into the construction of the first phase of the project, and about 2 billion yuan into research and development. The R&D and production headquarters will help at least one innovative drug product be approved for marketing in the next five years.

The second phase of the project will be used to expand commercial and new drug production capacity. It will also include incubation centers, R&D laboratories, and logistical and supporting facilities.

Established in 2017, Dizal Pharmaceutical has become the world leader in translational science, new-drug molecular design and screening technology platforms. It has accumulated extensive experience in the development of innovative therapies for the treatment of cancer, immunological diseases and chronic kidney diseases.

Zhang Xiaolin, chairman of Dizal Pharmaceutical, said that Wuxi has provided a good business environment for the company's development, and added that the company will continue to pursue innovation and work with Wuxi to build a globally competitive biopharmaceutical industry cluster.